Navigation Links
Mylan Launches First Generic Version of Entocort EC® Capsules
Date:6/23/2011

PITTSBURGH, June 23, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that the U.S. District Court for the District of Delaware has found after trial that Mylan subsidiary Mylan Pharmaceuticals Inc. does not infringe the asserted claims of U.S. Patent No. 5,643,602 with its Abbreviated New Drug Application (ANDA) for Budesonide Capsules, 3 mg (Enteric Coated), the generic version of AstraZeneca's Entocort EC® capsules, a treatment for Crohn's disease.  

Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Budesonide Capsules, 3 mg, ANDA on May 16. This is the first generic version of this product to be introduced to the U.S. market, and Mylan Pharmaceuticals will be shipping this product immediately.

Budesonide Capsules, 3 mg, had U.S. sales of approximately $350 million for the 12 months ending March 31, 2011, according to IMS Health.

Currently, Mylan has 164 ANDAs pending FDA approval representing $94.2 billion in annual sales, according to IMS Health. Forty-five of these pending ANDAs are potential first-to-file opportunities, representing $25.8 billion in annual brand sales, for the 12 months ending Dec. 31, 2010, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Mylan Receives Approval for Generic Version of Aricept® Tablets
2. Mylan Receives Approval for Generic Version of Effexor XR® Capsules
3. Mylan Launches Generic Version of Roxicodone® Tablets
4. Mylan Launches Generic Version of Depakote® Sprinkle Capsules
5. Mylan Launches First Generic Version of Xibrom® Ophthalmic Solution
6. Mylan Launches First Generic Version of Amrix® Capsules
7. Mylan Launches Generic Version of Risperdal® M-Tab®
8. Mylan Launches First Generic Version of Femara® Tablets
9. Mylan Launches Generic Version of Famvir® Tablets
10. Mylan Receives Approval for Generic Version of Xalatan® Ophthalmic Solution
11. Mylan Announces Exclusive Distribution Partnership with Humeca to Expand Burn and Wound Care Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014  In any given hospital in ... patients has at least one hospital-acquired infection, according to ... many of these infections prove fatal. And as increased ... number of patient deaths per year, infection control efforts ... Consequently, a stronger emphasis is being placed ...
(Date:7/24/2014)... , July 24, 2014 /PRNewswire-iReach/ -- Delivery of ... order is placed. Photo - ... professional and in-depth market survey on Global and ... the basic information of Hemodialysis Machine including its ... explores global and China,s top manufacturers of Hemodialysis ...
(Date:7/24/2014)... -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR ) today ... 2014. Three Months Ended 06/30/14Three Months Ended 06/30/13 ,  Percentage ... 51% Non-GAAP Net Sales , $278.8 Million , $196.1 ... , $1.12 , 37% Non-GAAP Diluted ... 37%  Six Months Ended 06/30/14Six Months Ended 06/30/13 , ...
Breaking Medicine Technology:Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 2Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5Questcor Reports Record Second Quarter Financial Results 2Questcor Reports Record Second Quarter Financial Results 3Questcor Reports Record Second Quarter Financial Results 4Questcor Reports Record Second Quarter Financial Results 5Questcor Reports Record Second Quarter Financial Results 6Questcor Reports Record Second Quarter Financial Results 7Questcor Reports Record Second Quarter Financial Results 8Questcor Reports Record Second Quarter Financial Results 9Questcor Reports Record Second Quarter Financial Results 10Questcor Reports Record Second Quarter Financial Results 11Questcor Reports Record Second Quarter Financial Results 12Questcor Reports Record Second Quarter Financial Results 13Questcor Reports Record Second Quarter Financial Results 14Questcor Reports Record Second Quarter Financial Results 15Questcor Reports Record Second Quarter Financial Results 16Questcor Reports Record Second Quarter Financial Results 17Questcor Reports Record Second Quarter Financial Results 18Questcor Reports Record Second Quarter Financial Results 19Questcor Reports Record Second Quarter Financial Results 20Questcor Reports Record Second Quarter Financial Results 21Questcor Reports Record Second Quarter Financial Results 22Questcor Reports Record Second Quarter Financial Results 23Questcor Reports Record Second Quarter Financial Results 24Questcor Reports Record Second Quarter Financial Results 25Questcor Reports Record Second Quarter Financial Results 26Questcor Reports Record Second Quarter Financial Results 27Questcor Reports Record Second Quarter Financial Results 28
... PharmAthene, Inc. (NYSE Amex: ... biological and chemical threats, announced today that the Company,s ... the position of President and Chief Executive Officer, effective ... Chief Executive Officer in May 2010, and prior thereto ...
... Inc., today reported positive clinical trial results on ... inhalation), an antibiotic that is entering Phase III ...  The results demonstrate significant clinical benefit and complete ... of lung infections due to the bacterium, ...
Cached Medicine Technology:PharmAthene Appoints Eric I. Richman President and Chief Executive Officer 2PharmAthene Appoints Eric I. Richman President and Chief Executive Officer 3ARIKACE™ Demonstrates Sustained Benefit in Multiple Studies and Over Multiple Cycles of Treatment of Pseudomonas Lung Infections in Cystic Fibrosis Patients 2ARIKACE™ Demonstrates Sustained Benefit in Multiple Studies and Over Multiple Cycles of Treatment of Pseudomonas Lung Infections in Cystic Fibrosis Patients 3ARIKACE™ Demonstrates Sustained Benefit in Multiple Studies and Over Multiple Cycles of Treatment of Pseudomonas Lung Infections in Cystic Fibrosis Patients 4ARIKACE™ Demonstrates Sustained Benefit in Multiple Studies and Over Multiple Cycles of Treatment of Pseudomonas Lung Infections in Cystic Fibrosis Patients 5
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 Just ... seriously, they must consider their own financial and marketing ... and weak marketing campaigns to the next level by ... Cloud Call Center, IVR, Voice Broadcast, Call Tracking and ... a 98% open rate, text messages are quickly become ...
(Date:7/24/2014)... Executives (ASAE) announced its 2014 Power of A Award ... of Anesthesiologists (ASA). , The ASA Global Humanitarian ... Award, one of the top honors from ASAE. GHO ... world through education on the global anesthesia crisis and ... ASA was also honored with a Power of A ...
(Date:7/24/2014)... (DM) appears to increase the risk for head and neck ... people with DM, but the risk of HNC in patients ... neck cancer is the sixth most common type of cancer. ... for an estimated 650,000 new cancer cases and 350,000 cancer ... Health Insurance Research Database to examine the risk of HNC ...
(Date:7/24/2014)... Primary care treatment of overweight and obese preschoolers ... compared to when only the child is targeted, according ... and conducted at the University at Buffalo and Women ... study were overweight or obese and had one parent ... or obese, according to body mass index (BMI) measurements, ...
(Date:7/24/2014)... Drinking caffeine may worsen the hot flashes and night ... go through menopause, new survey data suggests. "While ... caffeine intake may be useful for those postmenopausal women ... researcher Dr. Stephanie Faubion, director of the Women,s Health ... But caffeine -- a stimulant found in coffee and ...
Breaking Medicine News(10 mins):Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 2Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 3Health News:Overweight and obese preschoolers lose more weight when parent is also treated 2Health News:Overweight and obese preschoolers lose more weight when parent is also treated 3Health News:Is Coffee Aggravating Your Hot Flashes? 2
... Systems, a premier,provider of integrated professional and technical ... announced today that the Texas,Organization of Rural and ... Health Systems, Inc. endorsed vendor status.,Prior to endorsing ... certain the vendor is qualified to serve its ...
... Leadership authority is,critical for market research high ... leader to help optimize the market research group. ... market research,groups -- where top companies employ a ... and activities across Market,Research divisions, units and geographies., ...
... Passing ABC Plan; Urges Senate to,Act Quickly, ... today praised the House of Representatives for taking ... to Basic Care (PA ABC) plan,and he urged ... PA ABC would provide access to health care ...
... Also Announces Internal Controls and Procedures Improvements, Corporate, ... MCLEAN, Va., March 18 Sunrise Senior Living,Inc. ... informed the New York Stock,Exchange ("NYSE") that the Company ... deadline for filing its 2006 Form 10-K. The Company ...
... beneficial effects on human health, have been used for ... disorders. However, the ways in which probiotic bacteria elicit ... the action mechanisms could be the ability to induce ... At present there is only a limited amount of ...
... The Gram negative bacterium H pylori is involved in ... gastric carcinoma. Adhesion of the bacteria to the gastric ... , It is therefore important to know factors that ... MUC1, a mucin with a highly variable repetitive region ...
Cached Medicine News:Health News:Texas Organization of Rural and Community Hospitals (TORCH) Awards Phoenix Health Systems Endorsed Vendor Status 2Health News:Create Strong Leadership to Add Value to Market Research Function 2Health News:Governor Rendell Says Pennsylvania is One Step Closer to Providing Access to Health Care for Pennsylvania's Uninsured 2Health News:Governor Rendell Says Pennsylvania is One Step Closer to Providing Access to Health Care for Pennsylvania's Uninsured 3Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 2Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 3Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 4Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 5Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 6Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 7Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 8Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 9Health News:Do bacterial combinations result in enhanced cytokine production? No! 2
Anis tying forcep is extra delicate with smooth jaws, curved. For 9-0 to 11-0 sutures....
Curved shafts and tips with tying surfaces. Wide serrated handle with dull finish. Overall length 4.3 inches....
Straight heavy shafts with 7 mm tying surface. Wide serrated handle, polished finish. Overall length 4.2 inches....
Straight shafts with 6 mm tying platform. Serrated handle with polished finish. Most popular size or model. Overall length 4 inches....
Medicine Products: